Broad Tricyclic Ring Inhibitors Block SARS-CoV-2 Spike Function Required for Viral Entry-Reference-Cited by-同舟云学术

Broad Tricyclic Ring Inhibitors Block SARS-CoV-2 Spike Function Required for Viral Entry

Published:2022-09-26 Issue:10 Volume:8 Page:2045-2058
ISSN:2373-8227
Container-title:ACS Infectious Diseases
language:en
Short-container-title:ACS Infect. Dis.

Author:

Ratnapriya Sneha¹,Braun Anthony R.²^ORCID,Cervera Benet Héctor¹,Carlson Danielle¹,Ding Shilei³,Paulson Carolyn N.²^ORCID,Mishra Neeraj⁴,Sachs Jonathan N.²^ORCID,Aldrich Courtney C.⁴^ORCID,Finzi Andrés³,Herschhorn Alon¹⁵⁶⁷^ORCID

Affiliation:

1. Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, United States

2. Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota 55455, United States

3. Centre de Recherche du CHUM; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec H2X 0A9, Canada

4. Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, United States

5. Microbiology, Immunology, and Cancer Biology Graduate Program, University of Minnesota, Minneapolis, Minnesota 55455, United States

6. The College of Veterinary Medicine Graduate Program, University of Minnesota, Minneapolis, Minnesota 55455, United States

7. Institute for Molecular Virology, University of Minnesota, Minneapolis, Minnesota 55455, United States

Funder

University of Minnesota

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Infectious Diseases

Link

https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.1c00658

Reference55 articles.

1. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

2. A Novel Coronavirus from Patients with Pneumonia in China, 2019

3. SARS-CoV-2 vaccines in development

4. NCT04338906. Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19, 2020. https://clinicaltrials.gov/show/NCT04338906.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mRNA-based HIV-1 vaccines;Clinical Microbiology Reviews;2024-09-12

2. Alternative substitutions of N332 in HIV-1 _AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan;mBio;2024-04-10

3. Ultrasensitive quantification of HIV-1 cell-to-cell transmission in primary human CD4 ⁺ T cells measures viral sensitivity to broadly neutralizing antibodies;mBio;2024-01-16

4. Alternative substitutions of N332 in HIV-1_AD8gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan;2023-11-21

5. Ultrasensitive quantification of HIV-1 cell-to-cell transmission in primary human CD4⁺T cells measures viral sensitivity to broadly neutralizing antibodies;2023-09-09